Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Dec;119(12):1471-1476.
doi: 10.1038/s41416-018-0322-4. Epub 2018 Nov 14.

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Alison M Schram  1 , Leena Gandhi  2 , Monica M Mita  3 , Lars Damstrup  4 , Frank Campana  5 , Manuel Hidalgo  6 , Enrique Grande  7 , David M Hyman  8 , Rebecca S Heist  9
Affiliations
Clinical Trial

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Alison M Schram et al. Br J Cancer. 2018 Dec.

Abstract

Background: This phase Ib study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of pimasertib (MSC1936369B), a MEK1/2 inhibitor, in combination with voxtalisib (SAR245409), a pan-PI3K and mTORC1/mTORC2 inhibitor, in patients with advanced solid tumours.

Methods: This study included a dose escalation and expansion in patients with select tumour types and alterations in the MAPK or PI3K pathways. A 3 + 3 design was used to determine MTD. Patients were evaluated for adverse events and tumour response.

Results: 146 patients were treated, including 63 in dose escalation and 83 in expansion. The MTD was pimasertib 90 mg and voxtalisib 70 mg daily. Based on the safety profile, the recommended phase 2 dose (RP2D) was pimasertib 60 mg and voxtalisib 70 mg. The most frequent treatment-emergent adverse events (TEAEs) were diarrhoea (75%), fatigue (57%), and nausea (50%). Responses included a complete response in one patient (1%), partial response in five (5%), and stable disease in 51 (46%). At the RP2D, 74 patients required dose interruption (73%), 20 required dose reduction (20%), and 26 discontinued treatment due to TEAEs (26%).

Conclusions: The combination of pimasertib and voxtalisib showed poor long-term tolerability and limited anti-tumour activity in patients with advanced solid tumours.

PubMed Disclaimer

Conflict of interest statement

L.G.: Research Fuding: Merck. Advisory Role: Merck, Genentech/Roche, Pfizer, Ignyta, Syndax, AbbVie, AstraZeneca, Bristol-Myers Squibb; L.D.: Employee of Merck KGaA; F.C.: Employee of Sanofi; D.M.H.: Research Funding: NIH R01 CA204749, AstraZeneca, Puma Biotechnology, Loxo Oncology. Consulting or Advisory Role: AstraZeneca, Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, Pfizer, Genetech, Bayer, Debiopharm, ArQule; R.S.H.: Consulting: Boehringer Ingelheim. Research funding (to institution): Novartis, Celgene, Corvus, Genentech/Roche, Millenium, Mirati, ABBVie, Incyte, Exelixis, Daichi, Agios.

Figures

Fig. 1
Fig. 1
Dose-escalation schedule
Fig. 2
Fig. 2
Maximum change in tumour size at the RP2D, according to tumour type
See this image and copyright information in PMC

References

    1. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274. doi: 10.1016/j.cell.2007.06.009. - DOI - PMC - PubMed
    1. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer. 2004;4:937–947. doi: 10.1038/nrc1503. - DOI - PubMed
    1. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi: 10.1038/nature00766. - DOI - PubMed
    1. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J. Pathol. 2011;223:219–229. doi: 10.1002/path.2796. - DOI - PubMed
    1. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug. Discov. 2014;13:828–851. doi: 10.1038/nrd4389. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances